New data released by CLIMB Bio and MabWorks reveals that their investigational drug CLYM116 significantly reduces critical biomarkers associated with IgA nephropathy by approximately 70%. The findings underscore the drug’s potent ability to suppress disease markers, highlighting its therapeutic promise. Additionally, the data supports a convenient 12-week dosing schedule, which could improve patient adherence and treatment outcomes. IgA nephropathy, a common kidney disorder, currently lacks highly effective treatment options, making CLYM116 a potentially groundbreaking therapy. The robust biomarker suppression and favorable dosing frequency demonstrated in this study mark an important step forward in addressing this chronic condition. These promising results position CLYM116 as a leading candidate in the management of IgA nephropathy, offering hope for patients and clinicians alike. Continued clinical evaluation will clarify its full potential and long-term benefits.
PluangNew data shows tanker carrying 40,000 tons of Russian diesel bound for New York following Putin-Trump deal
October 24, 2026
New data reveals that a tanker loaded with 40,000 tons of Russian diesel is en route to New York after a recent agreement between Russian